Company profile: Merus Labs
1.1 - Company Overview
Company description
- Provider of pharmaceutical products across broad therapeutic classes, leveraging an opportunistic product acquisition strategy to source acquisition candidates and access targets not available to other players.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Merus Labs
Sagimet Biosciences
HQ: United States
Website
- Description: Provider of novel therapeutics targeting FASN, including Denifanstat, an oral, once-daily selective FASN inhibitor in development for MASH, acne, and certain cancers, and TVB-3567, a pipeline FASN inhibitor planned for U.S. clinical development for acne.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sagimet Biosciences company profile →
Salix Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals focused on preventing and treating gastrointestinal disorders, licensing, developing, and marketing therapies including XIFAXAN for IBS-D and reducing overt hepatic encephalopathy recurrence; RELISTOR for opioid-induced constipation; TRULANCE for chronic idiopathic constipation and IBS-C; UCERIS for ulcerative colitis; MOVIPREP and PLENVU for colonoscopy bowel preparation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salix Pharmaceuticals company profile →
Galectin Therapeutics
HQ: United States
Website
- Description: Provider of galectin-targeted therapeutics and research support, including belapectin (GR-MD-02) in clinical trials for NASH cirrhosis, cancer immunotherapy, and other fibrotic diseases; the NAVIGATE Phase 2b/3 study to prevent esophageal varices in NASH cirrhosis; combination trials with KEYTRUDA; discovery programs for small-molecule and carbohydrate galectin inhibitors; and galectin-3 inhibitor resources for preclinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galectin Therapeutics company profile →
Nurix Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics and discovery via the DELigase platform leveraging E3 ligases and DNA-encoded libraries for targeted protein degradation (TPD) and elevation (TPE). Pipeline includes oral candidates NX-5948 (BTK degrader), NX-2127 (BTK/IKZF1/IKZF3 degrader), and NX-1607 (CBL-B inhibitor) for B-cell malignancies, solid tumors, and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nurix Therapeutics company profile →
KalVista Pharmaceuticals
HQ: United States
Website
- Description: Provider of oral plasma kallikrein inhibitors for on-demand treatment of hereditary angioedema (HAE), including Sebetralstat being evaluated in the KONFIDENT Phase 3 Trial; developer of oral Factor XIIa inhibitors to prevent thrombosis with reduced bleeding risk; and other oral therapies targeting the kallikrein-kinin system, including HAE. An ophthalmology company with a focus on diabetic macular edema (DME).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KalVista Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Merus Labs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Merus Labs
2.2 - Growth funds investing in similar companies to Merus Labs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Merus Labs
4.2 - Public trading comparable groups for Merus Labs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →